WHO: Indian strain of COVID-19 resistant to antibodies
Mutations of the Indian strain of COVID-19 indicate its high infectivity and resistance to antibodies in both those who have been ill and vaccinated, the World Health Organization reported.
New varieties of the virus have been discovered in India, including B.1.617. It is a variant with mutations E484Q and L452R that was first identified in India from samples collected on December 1, 2020.
According to preliminary research results, the L452R mutation may interfere with the effectiveness of certain monoclonal antibody treatments. E484Q can neutralize antibodies. Thus, the antibodies that have appeared in a person who has recovered from COVID-19 will not help in the fight against Indian mutations.
Moreover, the new strain is also thought to be highly virulent, which means it is more likely to infect and cause disease.
WHO experts have not yet figured out what influenced the virus mutations in India. One of the factors could be the holding of mass events that increased its spread, as well as the mitigation of antiquated measures in the country.




















Why the Pressure on Vahe Hakobyan Continues
Unforgettable Moments and a Profitable Offer at Myler. Idram&IDBank
Ucom Introduces Hecttor AI to Improve Call Center Communications
The Power of One Dram Donates 5,788,105 AMD to the City of Smile Charity Foundation
AraratBank Partners as General Sponsor of 4090 Charity Foundation's Five-Year Milestone Event
Converse Bank Successfully Completes Globbing Bond Placement
Idram Summarizes 2025
AraratBank Takes the Lead in Brand PR Performance
The FINTECH360 conference will be held in Yerevan from April 27 to 29